In conjunction with studies elucidating the role of aberrant DNA methylation in the pathogenesis of CRC, research conducted by Early Detection Research Network (EDRN) Principal Investigators (PIs) has illustrated the viability of serum methylated MLH1 as a blood-based biomarker for CRC detection. Here, MLH1 is linked to colorectal carcinoma.